Source - RNS
RNS Number : 8079L
Faron Pharmaceuticals Oy
05 October 2016
 

 


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Faron Pharmaceuticals Oy

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):



3. Full name of person(s) subject to the
notification obligation:
iii

Aviva plc & its subsidiaries    

4. Full name of shareholder(s)
 (if different from 3.):iv

Registered Holder:

 

BNY Norwich Union Nominees Limited       122,189*

 

Chase (GA Group) Nominees Limited        1,697,607*

 

State Street Nominees Limited                          319,947*

            * denotes direct interest

Chase (GA Group) Nominees Limited              79,797

Chase Nominees Limited                                     52,129



5. Date of the transaction and date on
which the threshold is crossed or
reached:
v

03 October 2016

6. Date on which issuer notified:

04 October 2016

7. Threshold(s) that is/are crossed or
reached:
vi, vii

9% to 8% Change at Combined Interest Level.  Figures are provided in accordance with provisions of your company articles and not in fulfilment of the requirements of the Transparency Directive.

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares


FI4000153309

2,305,769

As per last TR-1 Disclosure

2,305,769

As per last TR-1 Disclosure

2,271,669

2,139,743

131,926

8.13%

0.50%



B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

 

 





 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

 





Nominal

Delta



Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,271,669

8.63%

 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chains of controlled undertakings:-

 

Aviva Investors Global Services Limited:

·      Aviva plc (Parent Company)

·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 


Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease
to hold:


12. Date on which proxy holder will cease to hold
voting rights:


 

 


13. Additional information:


Figures are based on a total number of voting rights of  26,311,704 as per the Company's Results of Placing and Subscription, Issue of Equity and Director/PDMR Shareholding Announcement of

21 September 2016.

 

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

00 44 1603 684420

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBUBDGDGGBGLU

Related Charts

Aviva (AV.)

+17.75p (+3.82%)
delayed 18:15PM

Faron Pharmaceuticals (FARN)

0.00p (0.00%)
delayed 18:15PM